Genentech Announces Final Phase III Study Results of Avastin P...

PDL BioPharma Inc. (PDLI: Quote) announced it has filed a Notice of Arbitration against Genentech alleging that Genentech underpaid royalties going back to at least 2007. In 2009, PDL retained KPMG LLP to conduct an independent inspection of the ...

Herceptin , says Genentech has been underpaying since 2007, but the Swiss company is defending itself and negating the claims. PDL also says Genentech is not cooperating with efforts to have its books and records inspected in search of

Genentech, a member of the Roche Group, announced final results from the Phase III AVAglio study in people with newly diagnosed glioblastoma, the most common and aggressive form of primary brain cancer. In a release, the Company noted that final ...

CHICAGO, June 2 (UPI) -- In 2009, the U.S. granted accelerated approval to Genentech's drug Avastin -- now manufactured by Roche -- to treat patients with advanced brain cancer -- glioblastoma -- no longer responding to therapy, but a clinical study ...

THE WOODLANDS, Texas Mr. Northcott has held commercial roles in both U.S. and Global marketing for Avastin with Genentech and the Roche Group, having most recently served as International Business Leader for Avastin, leading global product ...

Filed under: Investing Saying that biotech Genentech had unpaid royalties due it going all the way back to 2007, PDL BioPharma announced this morning that it has filed for arbitration against the division of Roche Holdings . PDL said that ...

Hal Barron, Roche/Genentech chief medical officer, shares several new developments in treating cancer, including some promising results with Roche/Genentech

The effectiveness of Genentech and Roche's ( RHHBY.OB ) glioblastoma multiforme ( GBM ) treatment, Avastin, has recently been challenged raising concerns from physicians and patients alike that a huge void in patient care can develop if the FDA ...

Contact The Court of Appeal recently heard a case relating to Genentech's patent, which claimed the use of human vascular endothelial growth factor (hVEGF) antagonists for the treatment of non-cancerous diseases which are characterised by ...